Patheon, a provider of outsourced pharmaceutical development and manufacturing services that was founded in Canada in 1974, has filed with the U.S. Securities and Exchange Commission to launch an initial public offering. The terms of the offering have not yet been determined. Last year, Patheon was taken private by U.S. private equity firm JLL Partners, a backer of the company since 2007, and Dutch food and chemicals group Royal DSM. The deal valued the business at US$1.4 billion. Patheon was listed on the Toronto Stock Exchange until March 2014.
Patheon Files Registration for Initial Public Offering
Patheon, a leading global provider of outsourced pharmaceutical development and manufacturing services through its end-to-end integrated service offering, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717 or via telephone: +1 (866) 803-9204 or, from Morgan Stanley & Co. LLC, Attention: Prospectus Department., 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone: +1 (866) 718-1649 or by email: firstname.lastname@example.org.
The registration statement on Form S-1 filed with the SEC has not yet become effective and the shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Patheon Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. The company is owned by JLL Partners and Royal DSM.
FOR FURTHER INFORMATION PLEASE CONTACT:
Tyler Gronbach Tel: +1 (919) 210-0986 Email: email@example.com firstname.lastname@example.org
Photo courtesy of Shutterstock